URANIUM ROYALTY CORP (UROY) Fundamental Analysis & Valuation

NASDAQ:UROY • CA91702V1013

3.56 USD
-0.23 (-6.07%)
At close: Mar 6, 2026
3.53 USD
-0.03 (-0.84%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This UROY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, UROY scores 2 out of 10 in our fundamental rating. UROY was compared to 207 industry peers in the Oil, Gas & Consumable Fuels industry. No worries on liquidiy or solvency for UROY as it has an excellent financial health rating, but there are worries on the profitability. UROY is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. UROY Profitability Analysis

1.1 Basic Checks

  • In the past year UROY has reported negative net income.
  • UROY had a positive operating cash flow in the past year.
  • UROY had negative earnings in 4 of the past 5 years.
  • In the past 5 years UROY always reported negative operating cash flow.
UROY Yearly Net Income VS EBIT VS OCF VS FCFUROY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • UROY has a worse Return On Assets (0.15%) than 67.15% of its industry peers.
  • UROY has a Return On Equity of 0.15%. This is in the lower half of the industry: UROY underperforms 66.18% of its industry peers.
Industry RankSector Rank
ROA 0.15%
ROE 0.15%
ROIC N/A
ROA(3y)-0.51%
ROA(5y)-1.15%
ROE(3y)-0.57%
ROE(5y)-1.22%
ROIC(3y)N/A
ROIC(5y)N/A
UROY Yearly ROA, ROE, ROICUROY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

1.3 Margins

  • The Profit Margin of UROY (1.35%) is worse than 62.32% of its industry peers.
  • UROY has a Gross Margin of 15.75%. This is in the lower half of the industry: UROY underperforms 67.15% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 1.35%
GM 15.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UROY Yearly Profit, Operating, Gross MarginsUROY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. UROY Health Analysis

2.1 Basic Checks

  • UROY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for UROY has been increased compared to 1 year ago.
  • UROY has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, UROY has a worse debt to assets ratio.
UROY Yearly Shares OutstandingUROY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
UROY Yearly Total Debt VS Total AssetsUROY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 395.44 indicates that UROY is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of UROY (395.44) is better than 99.52% of its industry peers.
  • The Debt to FCF ratio of UROY is 0.01, which is an excellent value as it means it would take UROY, only 0.01 years of fcf income to pay off all of its debts.
  • UROY has a better Debt to FCF ratio (0.01) than 90.82% of its industry peers.
  • UROY has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • UROY has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. UROY outperforms 84.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Altman-Z 395.44
ROIC/WACCN/A
WACC8.1%
UROY Yearly LT Debt VS Equity VS FCFUROY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • UROY has a Current Ratio of 265.74. This indicates that UROY is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 265.74, UROY belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • A Quick Ratio of 80.66 indicates that UROY has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 80.66, UROY belongs to the best of the industry, outperforming 99.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 265.74
Quick Ratio 80.66
UROY Yearly Current Assets VS Current LiabilitesUROY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. UROY Growth Analysis

3.1 Past

  • UROY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -93.40%.
  • The Revenue has decreased by -0.90% in the past year.
EPS 1Y (TTM)-93.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-0.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.62%

3.2 Future

  • UROY is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -129.02% yearly.
  • UROY is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -37.84% yearly.
EPS Next Y600.6%
EPS Next 2Y-145.07%
EPS Next 3Y-129.02%
EPS Next 5YN/A
Revenue Next Year248.23%
Revenue Next 2Y-75.5%
Revenue Next 3Y-37.84%
Revenue Next 5YN/A

3.3 Evolution

UROY Yearly Revenue VS EstimatesUROY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M 50M
UROY Yearly EPS VS EstimatesUROY Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.05 -0.05

More info and screens

Find the best growth stocksShow best growing peers

1

4. UROY Valuation Analysis

4.1 Price/Earnings Ratio

  • The Forward Price/Earnings Ratio is negative for UROY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UROY Price Earnings VS Forward Price EarningsUROY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • The rest of the industry has a similar Price/Free Cash Flow ratio as UROY.
Industry RankSector Rank
P/FCF 24.85
EV/EBITDA N/A
UROY Per share dataUROY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as UROY's earnings are expected to decrease with -129.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-145.07%
EPS Next 3Y-129.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UROY Dividend Analysis

5.1 Amount

  • UROY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UROY Fundamentals: All Metrics, Ratios and Statistics

URANIUM ROYALTY CORP

NASDAQ:UROY (3/6/2026, 8:00:02 PM)

After market: 3.53 -0.03 (-0.84%)

3.56

-0.23 (-6.07%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)12-11
Earnings (Next)03-18
Inst Owners28.61%
Inst Owner Change14.04%
Ins Owners2.09%
Ins Owner ChangeN/A
Market Cap521.47M
Revenue(TTM)37.95M
Net Income(TTM)512.00K
Analysts75
Price Target4.07 (14.33%)
Short Float %5.54%
Short Ratio2.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.48%
PT rev (3m)7.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)66.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)26.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.72
P/FCF 24.85
P/OCF 23.97
P/B 2.15
P/tB 2.15
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)0.14
FCFY4.02%
OCF(TTM)0.15
OCFY4.17%
SpS0.19
BVpS1.66
TBVpS1.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.15%
ROE 0.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1.35%
GM 15.75%
FCFM 75.35%
ROA(3y)-0.51%
ROA(5y)-1.15%
ROE(3y)-0.57%
ROE(5y)-1.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Debt/EBITDA N/A
Cap/Depr 644.44%
Cap/Sales 2.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 5583.98%
Current Ratio 265.74
Quick Ratio 80.66
Altman-Z 395.44
F-Score5
WACC8.1%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y600.6%
EPS Next 2Y-145.07%
EPS Next 3Y-129.02%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.62%
Revenue Next Year248.23%
Revenue Next 2Y-75.5%
Revenue Next 3Y-37.84%
Revenue Next 5YN/A
EBIT growth 1Y-154.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year142.68%
EBIT Next 3Y3.56%
EBIT Next 5YN/A
FCF growth 1Y234.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y239.06%
OCF growth 3YN/A
OCF growth 5YN/A

URANIUM ROYALTY CORP / UROY FAQ

What is the fundamental rating for UROY stock?

ChartMill assigns a fundamental rating of 2 / 10 to UROY.


Can you provide the valuation status for URANIUM ROYALTY CORP?

ChartMill assigns a valuation rating of 1 / 10 to URANIUM ROYALTY CORP (UROY). This can be considered as Overvalued.


How profitable is URANIUM ROYALTY CORP (UROY) stock?

URANIUM ROYALTY CORP (UROY) has a profitability rating of 0 / 10.


What is the financial health of URANIUM ROYALTY CORP (UROY) stock?

The financial health rating of URANIUM ROYALTY CORP (UROY) is 8 / 10.